Paxman Past Earnings Performance
Past criteria checks 5/6
Paxman has been growing earnings at an average annual rate of 42.6%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 25.1% per year. Paxman's return on equity is 17.4%, and it has net margins of 10.4%.
Key information
42.6%
Earnings growth rate
41.6%
EPS growth rate
| Medical Equipment Industry Growth | 6.2% |
| Revenue growth rate | 25.1% |
| Return on equity | 17.4% |
| Net Margin | 10.4% |
| Next Earnings Update | 21 Feb 2025 |
Recent past performance updates
Recent updates
Revenues Not Telling The Story For Paxman AB (publ) (STO:PAX) After Shares Rise 25%
Nov 07
Is It Time To Consider Buying Paxman AB (publ) (STO:PAX)?
Oct 22Results: Paxman AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Aug 24Paxman (STO:PAX) Might Have The Makings Of A Multi-Bagger
Aug 07After Leaping 28% Paxman AB (publ) (STO:PAX) Shares Are Not Flying Under The Radar
Jul 18Even With A 29% Surge, Cautious Investors Are Not Rewarding Paxman AB (publ)'s (STO:PAX) Performance Completely
May 24Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Dec 23Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue
Aug 25Paxman AB (publ) (STO:PAX) Could Be Riskier Than It Looks
Jun 01Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Nov 20Is Paxman (STO:PAX) A Risky Investment?
Mar 07Paxman (STO:PAX) Is Making Moderate Use Of Debt
Mar 15Are Insiders Buying Paxman AB (publ) (STO:PAX) Stock?
Jan 22Reflecting on Paxman's (STO:PAX) Share Price Returns Over The Last Year
Dec 18
Revenue & Expenses Breakdown
How Paxman makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 253 | 26 | 65 | 0 |
| 30 Jun 24 | 248 | 29 | 64 | 0 |
| 31 Mar 24 | 236 | 24 | 61 | 0 |
| 31 Dec 23 | 221 | 8 | 59 | 0 |
| 30 Sep 23 | 208 | 1 | 58 | 0 |
| 30 Jun 23 | 188 | -2 | 55 | 0 |
| 31 Mar 23 | 173 | -7 | 53 | 0 |
| 31 Dec 22 | 157 | -10 | 49 | 0 |
| 30 Sep 22 | 143 | -2 | 73 | 0 |
| 30 Jun 22 | 125 | -12 | 70 | 0 |
| 31 Mar 22 | 111 | -18 | 65 | 0 |
| 31 Dec 21 | 105 | -13 | 62 | 0 |
| 30 Sep 21 | 93 | -23 | 61 | 0 |
| 30 Jun 21 | 87 | -21 | 57 | 0 |
| 31 Mar 21 | 80 | -22 | 54 | 0 |
| 31 Dec 20 | 83 | -19 | 54 | 0 |
| 30 Sep 20 | 90 | -6 | 56 | 0 |
| 30 Jun 20 | 96 | -1 | 56 | 0 |
| 31 Mar 20 | 102 | 6 | 58 | 0 |
| 31 Dec 19 | 96 | 3 | 57 | 0 |
| 30 Sep 19 | 90 | -4 | 50 | 0 |
| 30 Jun 19 | 83 | -5 | 49 | 0 |
| 31 Mar 19 | 75 | -6 | 47 | 0 |
| 31 Dec 18 | 69 | -7 | 46 | 0 |
| 30 Sep 18 | 58 | -9 | 37 | 0 |
| 30 Jun 18 | 50 | -10 | 35 | 0 |
| 31 Mar 18 | 43 | -9 | 33 | 0 |
| 31 Dec 17 | 36 | -7 | 31 | 0 |
Quality Earnings: PAX has high quality earnings.
Growing Profit Margin: PAX's current net profit margins (10.4%) are higher than last year (0.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PAX has become profitable over the past 5 years, growing earnings by 42.6% per year.
Accelerating Growth: PAX's earnings growth over the past year (4243.6%) exceeds its 5-year average (42.6% per year).
Earnings vs Industry: PAX earnings growth over the past year (4243.6%) exceeded the Medical Equipment industry 31%.
Return on Equity
High ROE: PAX's Return on Equity (17.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 14:55 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Paxman AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mats Hyttinge | Redeye |